



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL
FORM 25-A

[See Rule 70-A]

Loan licence to manufacture for sale [or for distribution of] drugs other than those specified in [Schedules C, C(1) and X]

1. Number of licence and date of issue 21 14 4376 dt. 02.11.2021

2. M/s. Generic Health Care Pvt. Ltd., A-69 & A-70, PIPDIC Electronic Park, Thirubuvanaï, Mannadipet Commune, Puducherry – 605 107 is hereby granted a loan licence to manufacture the following drugs being drugs other than those specified in [Schedules C, C(1) and X] to the Drugs and Cosmetics Rules, 1945, on the premises situated at R.S No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 C/o. Sai Primus Life Biotech Pvt. Ltd., under the direction and supervision of the following [competent technical staff]:

- (a) Competent technical staff names: As per the expert Staff endorsed in the licences Of M/s. Sai Primus Life Biotech Pvt. Ltd., Puducherry for Manufacturing and Testing.
(b) Names of drugs: As per Annexure (each item to be separately specified)

3. The licence authorizes the sale by way of wholesale dealing by the licensee and storage for sale by the licensee of the drug manufactured under the licence subject to the conditions applicable to licenses for sale.

4. The licence, unless sooner suspended or cancelled, shall remain valid perpetually. However, the compliance with the conditions of license and the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) and the Drugs and Cosmetics Rules, 1945 shall be assessed not less than once in three years or as needed as per risk based approach.

5. The licence is subject to the conditions stated below and to such other conditions as may be specified in the Rules for the time being in force under the Drugs and Cosmetics Act, 1940.




(V. KARTHIKEYAN)
LICENSING AUTHORITY

Date: 02.11.2021

Conditions of Licence

1. This licence [***] shall be kept on the approved premises and shall be produced on the request of an Inspector appointed under the Drugs and Cosmetics Act, 1940.
2. Any change in the [competent technical staff] named in the licence shall be forthwith reported to the Licensing Authority.
3. If the licensee wants to undertake during the currency of the licence to manufacture for sale additional drugs he should apply to the Licensing Authority for the necessary endorsement to the licence as provided in Rule 69-A. This licence will be deemed to extend to the drugs so endorsed.
4. [***]
5. The licensee shall inform the Licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change takes place unless, in the meantime, a fresh licence has been taken from the Licensing Authority in the name of the firm with the changed constitution.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

FORM 28-A

[See Rule 76-A]

Loan Licence to manufacture for sale [or for distribution of] drugs specified in
Schedules C and C (1) [excluding those specified in schedule X]

1. Number of licence and date of issue 21 23 4377 dt. 02.11.2021

2. M/s. Generic Health Care Pvt. Ltd., A-69 & A-70, PIPDIC Electronic Park, Thirubuvanai, Mannadipet Commune, Puducherry – 605 107 is hereby granted a loan licence to manufacture on the premises situated at R.S No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 C/o. Sai Primus Life Biotech Pvt. Ltd., the following drugs being drugs specified in Schedules C and C(1) (excluding those specified in Schedule X) to the Drugs and Cosmetics Rules, 1945.

Names of drugs: As per Annexure (each item to be separately specified)

3. Name of approved (Competent technical staff names): As per the expert Staff endorsed in the licences Of M/s. Sai Primus Life Biotech Pvt. Ltd., for Manufacturing and Testing.

3-A The license, unless sooner suspended or cancelled, shall remain valid perpetually. However, the compliance with the conditions of license and the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) and the Drugs and Cosmetics Rules, 1945 shall be assessed not less than once in three years or as needed as per risk based approach.

4. The license authorizes the sale by way of wholesale dealing by the licensee and storage for sale by the licensee of the drugs manufactured under the licence subject to the conditions applicable to licenses for sale.

5. The license is subject to the conditions stated below and to such other conditions as may be specified in the Rules for the time being in force under the Drugs and Cosmetics Act, 1940.



(V. KARTHIKEYAN)
LICENSING AUTHORITY

Date: 02.11.2021

Conditions of Licence

1. This licence [* * *] shall be kept on the approved premises and shall be produced at the request of an Inspector appointed under the Drugs and Cosmetics Act, 1940.
2. If the licensee wishes to undertake during the currency of the licence to manufacture any drug specified in Schedules C and/or C(1) [excluding those specified in Schedule X] not included above, he should apply to the Licensing Authority for the necessary endorsement as provided in Rule 75-A. This licence will be deemed to extend to the items so endorsed.
3. Any change in the [competent technical staff] shall be forthwith reported to the Licensing Authority.
4. [* * *]
5. The licensee shall inform the Licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change takes place unless, in the meantime, a fresh licence has been taken from the Licensing Authority in the name of the firm with the changed constitution.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

1st Floor, Department of Drugs Control,
Indira Nagar, Gorimedu,
Puducherry-605 006
0413-2353647
Mail: ddc.pon@gmail.com

No. 692/DDC/GHC L.L@SPLB/SPP/2025-07/627

Dated:30.07.2025

SPECIAL PRODUCT PERMISSION

The Special Product Permission to manufacture for export of Approved Drug/ Unapproved Drug/ Banned Drug/ New Drug Permitted to **M/s. Generic Healthcare Private Limited**, A69 A70 PIPDIC Electronic Park, Thirubuvanai, Mannadipet Commune, Puducherry – 605107 L.L @ **M/s. Sai Primus Life Biotech Private Limited** R.S. No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 under Licence in **Form 28A** bearing licence No. **21 23 4377** dated **02.11.2021** which shall remain valid perpetually, subject to the deposit of licence retention fee periodically as prescribed under the Drugs and Cosmetics Act 1940 and Rules 1945.

a. Details of the Product

CATEGORY – TABLETS

Sl. No.	Name of the Product	Composition	Pack Size	Quantity	Details of NOC from CDSCO, SZ
1	Ciprofloxacin Tablets BP 500 mg. Brand Name: BONCIPRO 500	Each film coated tablet contains: Ciprofloxacin Hydrochloride BP Equivalent to Ciprofloxacin 500 mg	2x10's	2,00,000 Tablets	NA/NOC Export/ 2025/003925 Dated- 25.03.2025

b. Details of the Purchase Order & Date: 1.PO No. PP/ADNA-FZCO/03/25/303 Date: - 03.02.2025
2.PO No. ABIL/GHPL/2025/03/203-FZCO
Date: - 06.02.2025

c. Name & Address of the Foreign Buyer: M/s. ADNA Biomed FZCO,
BCB2 511-SD92,
5th Floor Business Cluster- Bulding 2,
Commer City, Dubai,
United Arab Emirates – 25314.

d. Name & Address of the Trader: M/s.Alfa Biomed India Pvt. Ltd.
Gut No.67, 68 Naigaon (Maval),
Ahirwade Village Road,
Old Mumbai Pune Highway,
Maval, Pune, Maharashtra, 412106

e. Name & Address of the Consignee: M/s.PLANET PHARMA
Zac Du Grand Launay,
4 Avenue Victor Grignard,
76120 Le Grand Quevilly,
France.

Conditions of the Licence:

- The drug will be manufactured by the firm at **M/s. Generic Healthcare Private Limited, L.L @ M/s. Sai Primus Life Biotech Pvt Ltd**, R.S. No.- 4/3, Plot No.-33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry- 605009.

2. The batch(es) of the formulation manufactured for export shall undergo quality control testing before export.
3. The firm is requested to ensure that the entire quantity of the drug(s) manufactured is exported and no part of it is diverted for domestic sale in India. An undertaking to this effect on Non-judicial stamp paper shall be submitted by the firm to the State Licensing Authority.
4. The stocks of the drugs manufactured solely for export shall invariably bear the inscription "For Export Only" – "Not for Domestic consumption" on the labels affixed to their cartons/packaging.
5. The firm shall submit a certificate in the below mentioned format after completion of the export to the State Licensing Authority.

Sl. No.	Quantity of the Drug manufacture	Quantity exported to << Country>>	API quantity in hand (Kgs)
---------	----------------------------------	-----------------------------------	----------------------------

6. The firm shall maintain a separate stock register for quantities of API purchased for manufacturing, drug formulation manufactured, consignments exported and remaining stocks of the drugs and bulk drugs which will be open for a periodic inspection by the State as well as Central Drugs Control Authorities.
7. The firm shall submit the information pertaining to quantities of drugs manufactured, exported and stock in hand to the State Licensing Authority quarterly.
8. The firm shall ensure that in the event of non-materialisation of export due to cancellation of export orders, etc. the same shall be intimated to the concerned State Licensing Authority and the manufacturer shall ensure physical destruction of such stocks in the presence of State Licensing Authority.
9. The firm shall ensure that the drug for which "Special Product Permission" has been given shall cease to be manufactured or exported if the drug is prohibited in future in the importing country.
10. In the event of rejection of drug by the country of import, or banning of the drug in the interim in the importing country, the material will not be allowed to import.
11. The firm is required to obtain Export Authorisation from Narcotic Commission of India, Central Bureau of Narcotics, Gwalior before exporting the drug, in case of Narcotic drugs & Psychotropic substances.
12. The Special Product Permission is valid for one year from the date of issue.



(Dr. E. ANANDAKIROUCHENANE)
LICENSING AUTHORITY

To

M/s. Generic Healthcare Private Limited, L.L @

M/s. Sai Primus Life Biotech Private Limited, R.S. No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009.

Copy To:

The Deputy Drugs Controller,

Office of the Deputy Drug Controller,

Central Drugs Standard Control Organisation (South Zone), CDSCO Bhawan,

No. 37, Jothi Venkatachalam Street, Vepery, Chennai (India)- 600 006.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

1st Floor, Department of Drugs Control,
Indira Nagar, Gorimedu,
Puducherry-605 006
0413-2353647
Mail: ddc.pon@gmail.com

No. 692/DDC/GHC L.L@SPLB/SPP/2025-07/629

Dated:30.07.2025

SPECIAL PRODUCT PERMISSION

The Special Product Permission to manufacture for export of Approved Drug/ Unapproved Drug/ Banned Drug/ New Drug Permitted to **M/s. Generic Healthcare Private Limited**, A69 A70 PIPDIC Electronic Park, Thirubuvana, Mannadipet Commune, Puducherry – 605107 L.L @ **M/s. Sai Primus Life Biotech Private Limited** R.S. No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 under Licence in **Form 28A** bearing licence No. **21 23 4377** dated **02.11.2021** which shall remain valid perpetually, subject to the deposit of licence retention fee periodically as prescribed under the Drugs and Cosmetics Act 1940 and Rules 1945.

a. Details of the Product

CATEGORY – TABLETS

Sl. No.	Name of the Product	Composition	Pack Size	Quantity	Details of NOC from CDSCO, SZ
1	Ciprofloxacin Tablets BP 500 mg. Brand Name: BONCIPRO 500	Each film coated tablet contains: Ciprofloxacin Hydrochloride BP Equivalent to Ciprofloxacin 500 mg	2x10's	2,00,000 Tablets	NA/NOC Export/ 2025/003925 Dated- 25.03.2025

b. Details of the Purchase Order & Date: 1.PO No. PP/ALFA-I/03/25/300 Date: - 03.02.2025
2.PO No. ABIL/GHPL/2025/03/200 -I
Date: - 06.02.2025

c. Name & Address of the Foreign Buyer: M/s. Alfa Biomed Ltd,
38 Dublin Road, D 13 H9K3,
Dublin Sutton
Ireland – 72201.

d. Name & Address of the Trader: M/s.Alfa Biomed India Pvt. Ltd.
Gut No.67, 68 Naigaon (Maval),
Ahirwade Village Road,
Old Mumbai Pune Highway,
Maval, Pune, Maharashtra, 412106

e. Name & Address of the Consignee: M/s.PLANET PHARMA
Zac Du Grand Launay,
4 Avenue Victor Grignard,
76120 Le Grand Quevilly,
France.

Conditions of the Licence:

- The drug will be manufactured by the firm at **M/s. Generic Healthcare Private Limited**, L.L @ **M/s. Sai Primus Life Biotech Pvt Ltd**, R.S. No.- 4/3, Plot No.-33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry- 605009.

2. The batch(es) of the formulation manufactured for export shall undergo quality control testing before export.
3. The firm is requested to ensure that the entire quantity of the drug(s) manufactured is exported and no part of it is diverted for domestic sale in India. An undertaking to this effect on Non-judicial stamp paper shall be submitted by the firm to the State Licensing Authority.
4. The stocks of the drugs manufactured solely for export shall invariably bear the inscription "For Export Only" – "Not for Domestic consumption" on the labels affixed to their cartons/packaging.
5. The firm shall submit a certificate in the below mentioned format after completion of the export to the State Licensing Authority.

Sl. No.	Quantity of the Drug manufacture	Quantity exported to << Country>>	API quantity in hand (Kgs)
---------	----------------------------------	-----------------------------------	----------------------------

6. The firm shall maintain a separate stock register for quantities of API purchased for manufacturing, drug formulation manufactured, consignments exported and remaining stocks of the drugs and bulk drugs which will be open for a periodic inspection by the State as well as Central Drugs Control Authorities.
7. The firm shall submit the information pertaining to quantities of drugs manufactured, exported and stock in hand to the State Licensing Authority quarterly.
8. The firm shall ensure that in the event of non-materialisation of export due to cancellation of export orders, etc. the same shall be intimated to the concerned State Licensing Authority and the manufacturer shall ensure physical destruction of such stocks in the presence of State Licensing Authority.
9. The firm shall ensure that the drug for which "Special Product Permission" has been given shall cease to be manufactured or exported if the drug is prohibited in future in the importing country.
10. In the event of rejection of drug by the country of import, or banning of the drug in the interim in the importing country, the material will not be allowed to import.
11. **The firm is required to obtain Export Authorisation from Narcotic Commission of India, Central Bureau of Narcotics, Gwalior before exporting the drug, in case of Narcotic drugs & Psychotropic substances.**
12. The Special Product Permission is **valid for one year** from the date of issue.



(Dr. E. ANANDAKIROUCHENANE)
LICENSING AUTHORITY

To

M/s. Generic Healthcare Private Limited, L.L @

M/s. Sai Primus Life Biotech Private Limited, R.S. No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009.

Copy To:

The Deputy Drugs Controller,

Office of the Deputy Drug Controller,

Central Drugs Standard Control Organisation (South Zone), CDSCO Bhawan,
No. 37, Jothi Venkatachalam Street, Vepery, Chennai (India)- 600 006.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

1st Floor, Department of Drugs Control,
Indira Nagar, Gorimedu,
Puducherry-605 006
0413-2353647
Mail: ddc.pon@gmail.com

No. 692/DDC/GHC L.L.@SPLB/SPP/2025-07/626

Dated:30.07.2025

SPECIAL PRODUCT PERMISSION

The Special Product Permission to manufacture for export of Approved Drug/ Unapproved Drug/ Banned Drug/ New Drug Permitted to **M/s. Generic Healthcare Private Limited**, A69 A70 PIPDIC Electronic Park, Thirubuvana, Mannadipet Commune, Puducherry – 605107 L.L @ **M/s. Sai Primus Life Biotech Private Limited** R.S. No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 under Licence in **Form 28A** bearing licence No. **21 23 4377** dated **02.11.2021** which shall remain valid perpetually, subject to the deposit of licence retention fee periodically as prescribed under the Drugs and Cosmetics Act 1940 and Rules 1945.

a. Details of the Product

CATEGORY – TABLETS

Sl. No.	Name of the Product	Composition	Pack Size	Quantity	Details of NOC from CDSCO, SZ
1	Ciprofloxacin Tablets BP 500 mg. Brand Name: BONCIPRO 500	Each film coated tablet contains: Ciprofloxacin Hydrochloride BP Equivalent to Ciprofloxacin 500 mg	2x10's	2,00,000 Tablets	NA/NOC Export/ 2025/003925 Dated- 25.03.2025

b. Details of the Purchase Order & Date: 1. PO No. PP/ALFA-M/03/25/306 Date: - 03.02.2025
2. PO No. ABIL/GHPL/2025/03/206-DUOPHARM Date: - 06.02.2025

c. Name & Address of the Foreign Buyer: M/s. ALFA BIOMED MAURITIUS LIMITED,
C/O Trident trust company limited,
5th floor Nexsky Building,
Ebene cybercity Mauritius – 72201.

d. Name & Address of the Trader: M/s.Alfa Biomed India Pvt. Ltd.
Gut No.67, 68 Naigaon (Maval),
Ahirwade Village Road,
Old Mumbai Pune Highway,
Maval, Pune, Maharashtra, 412106

e. Name & Address of the Consignee: M/s.DUOPHARM,
AGENCE ZONE INDUSTRIELLE, KM 2,
7 BLD, DU CENTENAIRE,
DE LA COMMUNE. DE, DEAKAR, 00000 B.P:14 441
DAKAR, SENEGAL.

Conditions of the Licence:

1. The drug will be manufactured by the firm at **M/s. Generic Healthcare Private Limited**, L.L @ **M/s. Sai Primus Life Biotech Pvt Ltd**, R.S. No.- 4/3, Plot No.-33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry- 605009.

2. The batch(es) of the formulation manufactured for export shall undergo quality control testing before export.
3. The firm is requested to ensure that the entire quantity of the drug(s) manufactured is exported and no part of it is diverted for domestic sale in India. An undertaking to this effect on Non-judicial stamp paper shall be submitted by the firm to the State Licensing Authority.
4. The stocks of the drugs manufactured solely for export shall invariably bear the inscription "For Export Only" – "Not for Domestic consumption" on the labels affixed to their cartons/packaging.
5. The firm shall submit a certificate in the below mentioned format after completion of the export to the State Licensing Authority.

Sl. No.	Quantity of the Drug manufacture	Quantity exported to << Country>>	API quantity in hand (Kgs)
---------	----------------------------------	-----------------------------------	----------------------------

6. The firm shall maintain a separate stock register for quantities of API purchased for manufacturing, drug formulation manufactured, consignments exported and remaining stocks of the drugs and bulk drugs which will be open for a periodic inspection by the State as well as Central Drugs Control Authorities.
7. The firm shall submit the information pertaining to quantities of drugs manufactured, exported and stock in hand to the State Licensing Authority quarterly.
8. The firm shall ensure that in the event of non-materialisation of export due to cancellation of export orders, etc. the same shall be intimated to the concerned State Licensing Authority and the manufacturer shall ensure physical destruction of such stocks in the presence of State Licensing Authority.
9. The firm shall ensure that the drug for which "Special Product Permission" has been given shall cease to be manufactured or exported if the drug is prohibited in future in the importing country.
10. In the event of rejection of drug by the country of import, or banning of the drug in the interim in the importing country, the material will not be allowed to import.
11. The firm is required to obtain Export Authorisation from Narcotic Commission of India, Central Bureau of Narcotics, Gwalior before exporting the drug, in case of Narcotic drugs & Psychotropic substances.
12. The Special Product Permission is **valid for one year** from the date of issue.



(Dr. E. ANANDAKIROUCHENANE)
LICENSING AUTHORITY

To

M/s. Generic Healthcare Private Limited, L.L @

M/s. Sai Primus Life Biotech Private Limited, R.S. No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009.

Copy To:

The Deputy Drugs Controller,

Office of the Deputy Drug Controller,

Central Drugs Standard Control Organisation (South Zone), CDSCO Bhawan,

No. 37, Jothi Venkatachalam Street, Vepery, Chennai (India)- 600 006.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

1st Floor, Department of Drugs Control,
Indira Nagar, Gorimedu,
Puducherry-605 006
0413-2353647
Mail: ddc.pon@gmail.com

No. 692/DDC/GHC L.L@SPLB/SPP/2025-07/628

Dated:30.07.2025

SPECIAL PRODUCT PERMISSION

The Special Product Permission to manufacture for export of Approved Drug/ Unapproved Drug/ Banned Drug/ New Drug Permitted to **M/s. Generic Healthcare Private Limited**, A69 A70 PIPDIC Electronic Park, Thirubuvana, Mannadipet Commune, Puducherry – 605107 L.L @ **M/s. Sai Primus Life Biotech Private Limited** R.S. No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 under Licence in **Form 28A** bearing licence No. **21 23 437** dated **02.11.2021** which shall remain valid perpetually, subject to the deposit of licence retention fee periodically as prescribed under the Drugs and Cosmetics Act 1940 and Rules 1945.

a. Details of the Product

CATEGORY – TABLETS

Sl. No.	Name of the Product	Composition	Pack Size	Quantity	Details of NOC from CDSCO, SZ
1	Ciprofloxacin Tablets BP 500 mg. Brand Name: BONCIPRO 500	Each film coated tablet contains: Ciprofloxacin Hydrochloride BP Equivalent to Ciprofloxacin 500 mg	2x10's	1,00,000 Tablets	NA/NOC Export/ 2025/003925 Dated- 25.03.2025

b. Details of the Purchase Order & Date: 1.PO No. GPB/GHPL/03/25/305 Date: - 03.02.2025
2.PO No. GHPL/2025/03/205-GAPOB Date: - 06.02.2025

c. Name & Address of the Foreign Buyer: M/s. ADNA GLOBAL LTD,
C/O TRIDENT TRUST COMPANY LIMITED,
5TH FLOOR NEXSKY BUILDING,
EBENE CYBERCITY MAURITIUS – 72201.

d. Name & Address of the Trader: M/s. Generic Healthcare Pvt. Ltd.
"City Square", 29/A, Office No. 205,
2nd floor, Behind Hotel Pride, Shivaji Nagar,
Pune – 411 005, Maharashtra, India.

e. Name & Address of the Consignee: M/s. GAPOB,
LOT 5208 PARCELLE A QUARTIER DANDJI,
PK 6 ROUTE DE PORTO NOVO,06 BP 06, COTONOU
REP. DU BENIN

Conditions of the Licence:

- The drug will be manufactured by the firm at **M/s. Generic Healthcare Private Limited, L.L @ M/s. Sai Primus Life Biotech Pvt Ltd**, R.S. No.- 4/3, Plot No.-33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry- 605009.

2. The batch(es) of the formulation manufactured for export shall undergo quality control testing before export.
3. The firm is requested to ensure that the entire quantity of the drug(s) manufactured is exported and no part of it is diverted for domestic sale in India. An undertaking to this effect on Non-judicial stamp paper shall be submitted by the firm to the State Licensing Authority.
4. The stocks of the drugs manufactured solely for export shall invariably bear the inscription "For Export Only" – "Not for Domestic consumption" on the labels affixed to their cartons/packaging.
5. The firm shall submit a certificate in the below mentioned format after completion of the export to the State Licensing Authority.

Sl. No.	Quantity of the Drug manufacture	Quantity exported to << Country>>	API quantity in hand (Kgs)
---------	----------------------------------	-----------------------------------	----------------------------

6. The firm shall maintain a separate stock register for quantities of API purchased for manufacturing, drug formulation manufactured, consignments exported and remaining stocks of the drugs and bulk drugs which will be open for a periodic inspection by the State as well as Central Drugs Control Authorities.
7. The firm shall submit the information pertaining to quantities of drugs manufactured, exported and stock in hand to the State Licensing Authority quarterly.
8. The firm shall ensure that in the event of non-materialisation of export due to cancellation of export orders, etc. the same shall be intimated to the concerned State Licensing Authority and the manufacturer shall ensure physical destruction of such stocks in the presence of State Licensing Authority.
9. The firm shall ensure that the drug for which "Special Product Permission" has been given shall cease to be manufactured or exported if the drug is prohibited in future in the importing country.
10. In the event of rejection of drug by the country of import, or banning of the drug in the interim in the importing country, the material will not be allowed to import.
11. The firm is required to obtain Export Authorisation from Narcotic Commission of India, Central Bureau of Narcotics, Gwalior before exporting the drug, in case of Narcotic drugs & Psychotropic substances.
12. The Special Product Permission is valid for one year from the date of issue.



(Dr. E. ANANDAKIROUCHENANE)
LICENSING AUTHORITY

To

M/s. Generic Healthcare Private Limited, L.L @

M/s. Sai Primus Life Biotech Private Limited, R.S. No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009.

Copy To:

The Deputy Drugs Controller,

Office of the Deputy Drug Controller,

Central Drugs Standard Control Organisation (South Zone), CDSCO Bhawan,
No. 37, Jothi Venkatachalam Street, Vepery, Chennai (India)- 600 006.



GOVERNMENT OF PUDUCHERRY
DEPARTMENT OF DRUGS CONTROL

1st Floor, Department of Drugs Control,
Indira Nagar, Gorimedu,
Puducherry-605 006
0413-2353647
Mail: ddc.pon@gmail.com

No. 692/DDC/GHC L.L@SPLB/SPP/2025-07/630

Dated:30.07.2025

SPECIAL PRODUCT PERMISSION

The Special Product Permission to manufacture for export of Approved Drug/ Unapproved Drug/ Banned Drug/ New Drug Permitted to **M/s. Generic Healthcare Private Limited**, A69 A70 PIPDIC Electronic Park, Thirubuvanai, Mannadipet Commune, Puducherry – 605107 L.L @ **M/s. Sai Primus Life Biotech Private Limited** R.S. No. 4/3, Plot No. 33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009 under Licence in **Form 28A** bearing licence No. **21 23 4377** dated **02.11.2021** which shall remain valid perpetually, subject to the deposit of licence retention fee periodically as prescribed under the Drugs and Cosmetics Act 1940 and Rules 1945.

a. Details of the Product

CATEGORY – TABLETS

Sl. No.	Name of the Product	Composition	Pack Size	Quantity	Details of NOC from CDSCO, SZ
1	Ciprofloxacin Tablets BP 500 mg. Brand Name: BONCIPRO 500	Each film coated tablet contains: Ciprofloxacin Hydrochloride BP Equivalent to Ciprofloxacin 500 mg	2x10's	1,00,000 Tablets	NA/NOC Export/ 2025/003925 Dated- 25.03.2025

b. Details of the Purchase Order & Date: 1.PO No. SBP/GHPL/03/304 Date: - 03.02.2025
2.PO No. GHPL/2025/03/204-SOBAPS Date: - 06.02.2025

c. Name & Address of the Foreign Buyer: M/s.SOCIETE BENINOISE POUR L'APPROVISIONNEMENT EN PRODUITS DE SANTE (SoBAPS) SA,
01 BP 3280 Cotonou - BENIN,
Sise au Quartier Enagnon Akpakpa.

d. Name & Address of the Trader: M/s.GENERIC HEALTHCARE PVT.LTD.
City Square, 29/A, Office No. 205, 2nd Floor, Behind Hotel Pride, Shivaji Nagar,
Pune-411005, India.

e. Name & Address of the Consignee: M/s.SOCIETE BENINOISE POUR L'APPROVISIONNEMENT EN PRODUITS DE SANTE (SoBAPS) SA,
01 BP 3280 Cotonou - BENIN,
Sise au Quartier Enagnon Akpakpa.

Conditions of the Licence:

1. The drug will be manufactured by the firm at **M/s. Generic Healthcare Private Limited, L.L @ M/s. Sai Primus Life Biotech Pvt Ltd**, R.S. No.- 4/3, Plot No.-33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry- 605009.

2. The batch(es) of the formulation manufactured for export shall undergo quality control testing before export.
3. The firm is requested to ensure that the entire quantity of the drug(s) manufactured is exported and no part of it is diverted for domestic sale in India. An undertaking to this effect on Non-judicial stamp paper shall be submitted by the firm to the State Licensing Authority.
4. The stocks of the drugs manufactured solely for export shall invariably bear the inscription "For Export Only" – "Not for Domestic consumption" on the labels affixed to their cartons/packaging.
5. The firm shall submit a certificate in the below mentioned format after completion of the export to the State Licensing Authority.

Sl. No.	Quantity of the Drug manufacture	Quantity exported to << Country>>	API quantity in hand (Kgs)
---------	----------------------------------	-----------------------------------	----------------------------

6. The firm shall maintain a separate stock register for quantities of API purchased for manufacturing, drug formulation manufactured, consignments exported and remaining stocks of the drugs and bulk drugs which will be open for a periodic inspection by the State as well as Central Drugs Control Authorities.
7. The firm shall submit the information pertaining to quantities of drugs manufactured, exported and stock in hand to the State Licensing Authority quarterly.
8. The firm shall ensure that in the event of non-materialisation of export due to cancellation of export orders, etc. the same shall be intimated to the concerned State Licensing Authority and the manufacturer shall ensure physical destruction of such stocks in the presence of State Licensing Authority.
9. The firm shall ensure that the drug for which "Special Product Permission" has been given shall cease to be manufactured or exported if the drug is prohibited in future in the importing country.
10. In the event of rejection of drug by the country of import, or banning of the drug in the interim in the importing country, the material will not be allowed to import.
11. The firm is required to obtain Export Authorisation from Narcotic Commission of India, Central Bureau of Narcotics, Gwalior before exporting the drug, in case of Narcotic drugs & Psychotropic substances.
12. The Special Product Permission is **valid for one year** from the date of issue.



(Dr. E. ANANDAKIROUCHENANE)
LICENSING AUTHORITY

To

M/s. Generic Healthcare Private Limited, L.L @

M/s. Sai Primus Life Biotech Private Limited, R.S. No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate, Villianur Commune, Puducherry – 605 009.

Copy To:

The Deputy Drugs Controller,

Office of the Deputy Drug Controller,

Central Drugs Standard Control Organisation (South Zone), CDSCO Bhawan,

No. 37, Jothi Venkatachalam Street, Vepery, Chennai (India)- 600 006.